SOURCE: Genomind

November 14, 2013 09:00 ET

Genomind Announces New Patient Outcomes Data Supporting Use of the Genecept Assay at NEI Global Psychopharmacology Congress

New Data Reported by Patients and Their Clinicians Shows Strong Efficacy

CHALFONT, PA--(Marketwired - November 14, 2013) - Genomind, a personalized medicine company, is pleased to announce that they will be sharing the results of their innovative Open Label Study in the poster session at the Neuroscience Education Institute (NEI) Global Psychopharmacology Congress, held November 14-16, 2013 in Colorado Springs, Colorado. The poster titled "An Open Label Study of Pharmacogenomic Based Treatment of Depression and Anxiety" will be shared on November 15, 2013. Genomind will also be exhibiting at booth #117.

The poster highlights preliminary results of a unique Open Label Study demonstrating that the Genecept™ Assay drives improved outcomes in psychiatric patients treated in real-world settings. This innovative study has 1,000 patients in entirety; the poster shares data on an initial group who finished baseline, one month and three month assessments. The following results were reported:

  • 72% of patients reported a diagnosis of Major Depressive Disorder or an Anxiety Disorder and the remaining patients reported diagnoses including ADHD, Bipolar Disorder and Schizophrenia
  • 68% of patients experienced 2 or more failed medication trials and over 28% had 5 or more
  • 81% of the patients showed "very much, much or some" improvement -- 56% were "very much or much" improved after intervention with the Genecept Assay
  • Patient reported outcomes showed reductions in the Zung Anxiety Scale and the UKU Side Effect Scale, and a statistically significant reduction in depression symptoms as measured by QIDs (p < 0.05)
  • Patient reported outcomes showed an increase in the QLES-Q, indicating an improvement in quality of life

"We are extremely excited to share preliminary data that indicates incorporation of pharmacogenomic information from the Genecept Assay into treatment of psychiatric patients improves symptoms and reduces medication side effects," said Dr. Jay Lombard, Chief Scientific Officer and Medical Director, Genomind. "This study design offers an efficient means of rapid data collection to help drive the growing body of research supporting pharmacogenetic testing."

This study provides new evidence that pharmacogenetic testing can inform treatment interventions, leading to improved patient outcomes as reported by both patients and clinicians. The poster shows that pharmacogenetic testing may help identify effective and appropriate therapies leading to reduced medication side effects, increased quality of life, and better symptom control.

About Genomind

Genomind is a personalized medicine company, comprised of innovative researchers and expert leaders in psychiatry and neurology. Genomind is committed to discovery of the underlying causes of neuropsychiatric disorders and supports the development of personalized medicine that improves patients' lives. Genomind was founded by Ronald I. Dozoretz, MD, a psychiatrist who has devoted his career to improving mental health. Jay Lombard, DO, a neurologist and co-founder of Genomind, is a critically acclaimed author and nationally recognized thought leader in neuropsychiatry practice and research. Learn more at http://www.genomind.com.

About the Genecept Assay

The Genecept Assay is a comprehensive, simple-to-use tool for understanding genetic and biological markers that best inform response to different psychiatric treatments. The Assay is Genomind's core product, and contains a proprietary panel of biomarker tests, an analytic report, and a psychopharmacologist consultation. The Assay can be used for a range of psychiatric conditions including depression, bipolar disorder, schizophrenia, anxiety disorders, OCD and ADHD. For more information on the Assay, including information about the specific genes in the panel, please visit http://www.genomind.com/products/assay.

Contact Information